申请人:Taiho Pharmaceutical Co., Ltd.
公开号:US09289431B2
公开(公告)日:2016-03-22
An antitumor effect potentiator for potentiating one or more other antitumor agents, comprising, as an active ingredient, an imidazooxazine compound represented by Formula (I), or a pharmaceutically acceptable salt thereof,
wherein A, B, C, and D represent C—R1a, C—R1b, C—R1c, and C—R1d, respectively, or one or two of A, B, C, and D represent an N atom;
at least two of R1a, R1b, R1c, and R1d represent hydrogen, and the other(s) represent(s) halogen; cyano; C1-6 alkyl that may have hydroxyl group(s) as substituent(s); C1-6 alkoxy; carbonyl having, as a substituent, hydroxyl, amino, optionally substituted mono- or di-(C1-6 alkyl)amino, or mono- or di-(C1-6 alkoxy)amino; or an unsaturated heterocyclic group;
R2 represents phenyl, pyridyl, or thienyl;
R3 represents hydrogen, methyl, ethyl, or cyclopropyl; and
R4 represents hydrogen or hydroxy.
一种抗肿瘤效应增强剂,用于增强一个或多个其他抗肿瘤药物的作用,包括作为活性成分的由式(I)表示的咪唑噁啉化合物或其药学上可接受的盐,其中A、B、C和D分别表示C-R1a、C-R1b、C-R1c和C-R1d,或者A、B、C和D中的一个或两个表示N原子;R1a、R1b、R1c和R1d中至少两个表示氢,其他的表示卤素;氰基;C1-6烷基,可以具有羟基取代物;C1-6烷氧基;具有羟基,氨基,可选择取代的单烷基或双烷基氨基,或单烷氧基或双烷氧基氨基作为取代基的羰基;或不饱和杂环基;R2表示苯基,吡啶基或噻吩基;R3表示氢,甲基,乙基或环丙基;R4表示氢或羟基。